Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography

Therapeutic Drug Monitoring

Volumn 27, Issue 2, 2005, Pages 186-192

  Poirier, Jean Marie ^a   Robidou, Pascal ^a   Jaillon, Patrice ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

High performance liquid chromatography; HIV protease inhibitors; Nonnucleoside reverse transcriptase inhibitors; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DRUG METABOLITE; EFAVIRENZ; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NELFINAVIR METABOLITE M8; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID LIQUID EXTRACTION; METABOLITE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS REPLICATION;

CALIBRATION; CARBAMATES; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; NEVIRAPINE; OLIGOPEPTIDES; OXAZINES; PYRIDINES; PYRIMIDINONES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; SPECIMEN HANDLING; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFONAMIDES;

EID: 16244405916     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000152680.36517.5d     Document Type: Article

References (16)

1. Pallela FJ, Delaney KM, Moorman AV, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Aarnoutse RE, Schapiro JM, Boucher CAB, et al. Therapeutic drug monitoring. An aid to optimizine response to antiretroviral drugs? Drugs. 2003;63:741-753.
3. Guiard-Schmid JB, Poirier JM, Meynard JL, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003;47:986-990.
4. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
5. De Maat MMR, Huitema ADR, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 2003;25:367-373.
6. Mallon PWG, Ray J, Cooper DA. Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol. 2003;26:223-227.
7. Titier K, Lagrange F, Pehourcq F, et al. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and the two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther Drug Monit. 2002;24:417-424.
8. Tribut O, Arvieux C, Michelet C, et al. Simultaneous quantitative assay of the six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit. 2002;24:554-562.
9. Schuster A, Burzawa A, Jemal M. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;788:377-386.
10. Jemal M, Rao S, Gatz M, et al. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;795:273-289.
11. Crommentuyn KML, Rosing H, Hillebrand MJX, et al. Simultaneous quantification of the new protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:359-367.
12. Turner ML, Reed-Walker K, King JR, et al. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:331-341.
13. Resk NL, Tidwell RR, Kashuba ADM. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805:241-247.
14. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS. 1996;10: 1361-1367.
15. Moore KH, Barrett JB, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239-2250.
16. th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002 [abstract 444-W].